Research programme: alkylating agents - MabVax

Drug Profile

Research programme: alkylating agents - MabVax

Alternative Names: TLK 58747

Latest Information Update: 10 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Telik
  • Developer MabVax Therapeutics
  • Class Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Nov 2010 Telik receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA)
  • 22 Apr 2009 Pharmacodynamics and adverse events data from preclinical trials of TLK 58747 in Cancer presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top